Medical Director, Clinical Development, Obesity

A typical mandate

The company develops oral small molecules targeting incretin pathways for obesity and related metabolic disease. Its lead compound has completed Phase 1 and is entering a dose-ranging Phase 2. The medical team is small, so this role carries real ownership of the study.

What the role owns

• Act as medical monitor and clinical lead for the Phase 2 dose-ranging study
• Write and refine protocols, investigator brochures and clinical study reports
• Review safety data with drug safety, including gastrointestinal tolerability and cardiovascular signals
• Contribute to dose selection and Phase 3 design with biostatistics and regulatory
• Build relationships with endocrinology and obesity medicine investigators
• Support FDA meeting preparation and briefing documents

What great candidates bring

• MD or DO, with training in endocrinology, cardiology or internal medicine
• 4+ years in industry clinical development, including medical monitoring
• Experience with Phase 2 or Phase 3 studies in metabolic or cardiovascular disease
• Sound clinical judgment on safety signals and benefit-risk
• Familiarity with FDA guidance on developing drugs for weight reduction
• Clear writing and a steady presence with investigators

Why it matters

• Reports to the Vice President, Clinical Development
• Equity at Series C
• Real ownership of a lead program at an important stage
• Hybrid schedule